ClinicalTrials.gg
Sign In
TerminatedNCT02158793Updated Jun 27, 2024

Craniomaxillofacial Allotransplantation

An interventional study of Craniomaxillofacial allotransplantation in Facial Injuries, sponsored by NYU Langone Health. Terminated at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

Why this study was terminated
It was determined that the study would be integrated into the standard clinical care.
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to perform face transplants on people who have suffered severe facial trauma with tissue and functional loss; and evaluate the acceptance and function of the transplanted tissue. The aim of the transplant is to provide patient a more normal appearance . Additionally we aim to restore functioning, movement, and sensation of their face including that of the lips, mouth, and eyes.

Read the detailed description

This study is to perform facial transplants in patients with severe facial deformities or facial wounds from traumatic injuries. The transplant is to help reconstruct a person's damaged face. The aim of the transplant is to provide patient a more normal appearance . Additionally we aim to restore functioning, movement, and sensation of their face including that of the lips, mouth, and eyes.

There are some procedures in plastic and reconstructive surgery that can repair the look of a patient's face, but often can't replace the movement and use of the face. Currently, patients with severe facial deformities would undergo several reconstructive surgeries with their own tissues, called autologous transplant. Conventional reconstruction method requires multiple surgeries in order to form and shape the transplanted tissue. Because this type of reconstruction is limited, it does not provide a reliable return in function, sensation, and appearance for the damaged parts of the face.

This study uses a composite tissue allograft , or face transplant from a donor who is brain dead such as in heart, kidney and liver transplants. The damaged parts of the face could return movement as well. Transplanted patients are required to take lifelong immunosuppression drugs which have risks, which are still a consideration when deciding to choose this option for correcting severe facial deformities.

We will conduct the surgery and prospectively follow the patient to monitor signs of rejection of the transplanted face. Additionally, patients will be constantly evaluated for clinical and functional outcomes and ensure that optimal results are achieved.

02

Conditions studied

  • Facial Injuries

Keywords

  • face transplant
  • Craniomaxillofacial Allotransplantation
  • facial disfigurement
  • facial trauma
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,421 studies on the registry; 254 are open to participants now.

Of its 231 completed or terminated interventional studies of FDA-regulated products, 195 (84%) have results posted.

Browse NYU Langone Health studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated all required IRB approved consent forms
  • Male or female recipient between the ages of 18-64 years. * Recipients do not need to be same gender as donor*
  • Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage.
  • Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction.
  • Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery
  • The subject is able to complete pre-transplant examination and screening procedures.
  • Patient has been approved by Patient Selection Committee for placement on the recipient waiting list
  • The subject is willing to continue immunosuppression regimen as directed by treating physician.
  • Subject is willing and able to return to follow-up visits as described in treatment plan.
  • Subjects must have autogenous tissue options available for reconstruction in event of graft failure.
  • Normal GFR (glomerular filtration rate) >60
  • Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant.

Exclusion criteria

Exclusion criteria:

  • Subject has an uncontrolled infection
  • Serious co-morbidities
  • Positive serology for HIV; Hepatitis B/C Antigen
  • Active malignancy within 5 years with the exclusion of non-melanoma
  • Subject has active substance abuse/ alcoholism
  • Active Severe Psychiatric Illness
  • Cognitive limitations affecting the patient's ability to provide informed consent
  • Recent history of medical nonadherence
  • Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other.
  • Recent history of medical non-adherence.
  • Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study
  • Currently active smoker within 1 year
  • Subjects with any cognitive deficits related to a TBI (traumatic brain injury) and or any organic neurological disorders will not be considered for this protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Face Transplant recipient

    Single Arm study, all participants will receive Craniomaxillofacial allotransplantation

    Procedure: Craniomaxillofacial allotransplantation

Interventions

  • ProcedureCraniomaxillofacial allotransplantation

    Transplantation of donor face

06

What researchers measure

Primary outcomes

  1. Evaluate the success of the face transplant

    We will measure the restoration of function, sensation, and appearance of the transplanted facial segment. These will be measured using various multi-disciplinary evaluations including swallow studies, photography, speech therapy evaluation, Occupational therapy evaluation, electromyogram (EMG) , Nerve Conduction Study (NCS), CT Angiogram, Functional ( Magnetic Resononance Image) MRI, vision exams, pathology samples to check for rejection, Blood tests

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

Secondary outcomes

  1. Evaluate psychological effects of receiving a face transplant

    Psychological outcome will be measured using patient reported outcome tools such as MoCA; BIDQ; SF-36; PHQ-9

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually until year 5

07

Study locations

1 site
  • NYU Langone Medical Center
    New York, New York 10016, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02158793
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jun 9, 2014
Start date
Jun 2014
Primary completion
Dec 11, 2023
Completion
Dec 11, 2023
Last update
Jun 27, 2024

Study contacts

Eduardo Rodriguez, MD, DDS
principal investigator · NYU Langone Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Facial Injuries

Other studies from this sponsor

NYU Langone Health →

Start the discussion